Search

Your search keyword '"Mahfouz, Rami"' showing total 613 results
Start Over "Mahfouz, Rami"
613 results on '"Mahfouz, Rami"'

253. Targeted Therapy with Arsenic Trioxide and Interferon alpha Eradicates Leukemic Cells in SCID Mice Model of Adult T-Cell Leukemia/Lymphoma.

Author

Hajj, Hiba El, primary, Hasegawa, Hideki, additional, El-Sabban, Marwan, additional, Zaatari, Ghazi, additional, Saab, Shehrazad, additional, Mahfouz, Rami, additional, Nasr, Rihab, additional, Kfoury, Youmna, additional, Hermine, Olivier, additional, de Thé, Hugues, additional, Hall, William, additional, and Bazarbachi, Ali, additional

Published
2007
Full Text
View/download PDF

264. Erratum 1

Author

Jamali, Faek R., primary, Otrock, Zaher K., additional, Soweid, Assaad M., additional, Al-Awar, Ghassan N., additional, Mahfouz, Rami A., additional, Haidar, Ghassan R., additional, and Bazarbachi, Ali, additional

Published
2007
Full Text
View/download PDF

265. Pulmonary Embolism in a Sarcoidosis Patient Double Heterozygous for Methylenetetrahydrofolate Reductase Gene Polymorphisms and Factor V Leiden and Homozygous for the D-Allele of Angiotensin Converting Enzyme Gene.

Author

El-Majzoub, Nadim, Mahfouz, Rami, and Kanj, Nadim

Subjects
SARCOIDOSIS treatment, PULMONARY embolism, METHYLENETETRAHYDROFOLATE reductase, ALLELES, ANGIOTENSIN converting enzyme, HOMOZYGOSITY, ETIOLOGY of diseases
Abstract

Sarcoidosis is a multisystem granulomatous disease of unknown etiology and pathogenesis. It presents in patients younger than 40 years of age. The lungs are the most commonly affected organ. Till the present day, there is no single specific test that will accurately diagnose sarcoidosis; as a result, the diagnosis of sarcoidosis relies on a combination of clinical, radiologic, and histologic findings. Patients with sarcoidosis have been found to have an increased risk of pulmonary embolism compared to the normal population. MTHFR and factor V Leiden mutations have been reported to increase the risk of thrombosis in patients. We hereby present a case of a middle aged man with sarcoidosis who developed a right main pulmonary embolism and was found to be double heterozygous for methylenetetrahydrofolate reductase gene polymorphisms and factor V Leiden and homozygous for the D-allele of the angiotensin converting enzyme gene. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

269. 108-P

Author

Mahfouz, Rami, primary, Mahfoud, Ziyad, additional, Rayyes, Roni, additional, Hajj, Nadi, additional, Arayssi, Thourayya, additional, and Zaatari, Ghazi, additional

Published
2006
Full Text
View/download PDF

282. Gene expression profiling of pediatric acute myelogenous leukemia

Author

Ross, Mary E., primary, Mahfouz, Rami, additional, Onciu, Mihaela, additional, Liu, Hsi-Che, additional, Zhou, Xiaodong, additional, Song, Guangchun, additional, Shurtleff, Sheila A., additional, Pounds, Stanley, additional, Cheng, Cheng, additional, Ma, Jing, additional, Ribeiro, Raul C., additional, Rubnitz, Jeffrey E., additional, Girtman, Kevin, additional, Williams, W. Kent, additional, Raimondi, Susana C., additional, Liang, Der-Cherng, additional, Shih, Lee-Yung, additional, Pui, Ching-Hon, additional, and Downing, James R., additional

Published
2004
Full Text
View/download PDF

286. Comparison between the accuracy of chest computerized tomography vs. reverse transcriptase polymerase chain reaction in a tertiary care center in Lebanon; along with their correlation to mortality, morbidity and symptoms in COVID-19 patients

Author

Hanania, Noor, Najem, Elie, Tamim, Hani, Assaf, Nada, Majari, Ghaidaa, Younes, Wael, Abbas, Fatmeh, Berjawi, Ghina, and Mahfouz, Rami

Abstract

Chest Computerized Tomography has been widely used in COVID patients' assessment. Hence the question arises as to whether there is any correlation between the Ct value and findings on Chest CT scan or clinical presentation of the patient. We wanted to test the hypothesis of whether low Ct values (≤30) in RT-PCR were associated with a high mortality rate, CT scan findings, or with comorbidities such as immunosuppression and lung disease.

Published
2023
Full Text
View/download PDF

288. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

Author

Yeoh, Eng-Juh, primary, Ross, Mary E, additional, Shurtleff, Sheila A, additional, Williams, W.Kent, additional, Patel, Divyen, additional, Mahfouz, Rami, additional, Behm, Fred G, additional, Raimondi, Susana C, additional, Relling, Mary V, additional, Patel, Anami, additional, Cheng, Cheng, additional, Campana, Dario, additional, Wilkins, Dawn, additional, Zhou, Xiaodong, additional, Li, Jinyan, additional, Liu, Huiqing, additional, Pui, Ching-Hon, additional, Evans, William E, additional, Naeve, Clayton, additional, Wong, Limsoon, additional, and Downing, James R, additional

Published
2002
Full Text
View/download PDF

291. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.

Author

El Cheikh, Jean, Massoud, Radwan, Haffar, Basel, Fares, Elie, Mahfouz, Rami, Jisr, Tamima, Kharfan-Dabaja, Mohamed A., Mougharbel, Anas, Youssef, Ali, Bazarbachi, Ali, and Ibrahim, Ahmad

Subjects
HODGKIN'S disease treatment, IMMUNOGLOBULIN G, MONOCLONAL antibodies, PROTEOLYTIC enzymes, HEMATOPOIETIC stem cell transplantation
Abstract

The article focuses on therapies named brentuximab vedotin (BV) and nivolumab for treatment of Hodgkin lymphoma (HL). Topics include information on BV which is an anti-CD30 chimeric Immunoglobulin G1 (IgG1) monoclonal antibody conjugated through protease-cleavable linker to antimicrotubule drug monomethyl auristatin E (MMAE); use of bendamustine, a chemotherapy medication before allogeneic hematopoietic stem cell transplantation; and use of salvage nivolumab upon failure of bendamustine.

Published
2017
Full Text
View/download PDF

293. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.

Author

El Eit, Rabab M., Iskandarani, Ahmad N., Saliba, Jessica L., Jabbour, Mark N., Mahfouz, Rami A., Bitar, Nizar M.A., Ayoubi, Hanadi R. El, Zaatari, Ghazi S., Mahon, Francois‐Xavier, De Thé, Hugues B., Bazarbachi, Ali A., and Nasr, Rihab R.

Abstract

Imatinib is the standard of care in chronic meloid leukemia (CML) therapy. However, imatinib is not curative since most patients who discontinue therapy relapse indicating that leukemia initiating cells (LIC) are resistant. Interferon alpha (IFN) induces hematologic and cytogenetic remissions and interestingly, improved outcome was reported with the combination of interferon and imatinib. Arsenic trioxide was suggested to decrease CML LIC. We investigated the effects of arsenic and IFN on human CML cell lines or primary cells and the bone marrow retroviral transduction/transplantation murine CML model. In vitro, the combination of arsenic and IFN inhibited proliferation and activated apoptosis. Importantly, arsenic and IFN synergistically reduced the clonogenic activity of primary bone marrow cells derived from CML patients. Finally, in vivo, combined interferon and arsenic treatment, but not single agents, prolonged the survival of primary CML mice. Importantly, the combination severely impaired engraftment into untreated secondary recipients, with some recipients never developing the disease, demonstrating a dramatic decrease in CML LIC activity. Arsenic/IFN effect on CML LIC activity was significantly superior to that of imatinib. These results support further exploration of this combination, alone or with imatinib aiming at achieving CML eradication rather than long-term disease control. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

295. Association of Human Leukocyte Antigens (HLA) profile and acute lymphoblastic leukemia in Lebanese pediatric patients: A first report from Lebanon

Author

El Karaaoui, AbdulKarim, Tamim, Hani, El Achkar, Hani, Fermanian, Puzant, Abbas, Fatmeh, Keleshian, Sose, Muwakkit, Samar, and Mahfouz, Rami

Abstract

Childhood acute lymphoblastic leukemia is thought to result due to interaction of genetic and environmental factors. The association between it and different alleles of the HLA system has been studied over the past decades in different countries.

Published
2022
Full Text
View/download PDF

296. Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma

Author

Antar, Ahmad, Ishak, Rim S., Otrock, Zaher K., El-Majzoub, Nadim, Ghosn, Samer, Mahfouz, Rami, and Taher, Ali T.

Abstract

Hydroxyurea (HU) is an antineoplastic drug used in the treatment of chronic myeloproliferative neoplasms (MPNs). HU is associated with cutaneous adverse effects, whereas severe complications such as leg ulcers and non-melanoma skin cancers (NMSCs) are rare and only observed after long-term treatment. We herein report a patient with essential thrombocythemia (ET) treated chronically with HU, and who developed refractory bilateral leg ulcers complicated by squamous cell carcinoma (SCC) over both heels. The patient was successfully managed by multiple debridement stages and skin grafting surgeries.

Published
2014
Full Text
View/download PDF

299. Should we screen for hereditary hemochromatosis in healthy Lebanese: a pilot study.

Author

Mahfouz, Rami, Sarieddine, Doja, Charafeddine, Khalil, Abdul Khalik, Rabab, Cortas, Najwa, and Daher, Rose

Abstract

Hereditary hemochromatosis (HHC) is a genetic disorder of iron metabolism characterized by abnormal accumulation of iron that may lead to organ damage and death. Diagnosis is usually based on various genetic and phenotypic criteria. The study goals were to perform mutation analysis for 18 different mutations associated with HHC in healthy Lebanese, determine their allele frequency, and compare iron-overload status in identified carriers versus those found to be wild-type for mutations analyzed. 116 healthy adults (59 males and 57 females) underwent DNA testing for 18 different HHC mutations, and biochemical testing for percent transferrin saturation (%TS) and ferritin. C282Y mutation was not detected. Only H63D mutation (rs1799945) was found with an overall carrier frequency of 25.8% (24.1% heterozygous and 1.7% homozygous). %TS and ferritin differed significantly between genders. %TS and ferritin were significantly higher in males with H63D mutation when compared to males with wild-type ( P = 0.001, 0.019; respectively); but not in females. The proportion of subjects with increased %TS and serum ferritin was not statistically different between those with H63D mutation and the wild-type in either gender. In addition, none of the subjects had concurrent increase in %TS and ferritin. In conclusion, the H63D carrier frequency in healthy Lebanese is comparable to other populations in the region, and it does not result in significant biochemical iron overload. Moreover, in the absence of the C282Y mutation, genetic screening for HHC is not recommended according to this preliminary study in healthy Lebanese. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

300. Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People.

Author

Esmerian, Maria O., Mitri, Zahi, Habbal, Mohammad-Zuheir, Geryess, Eddy, Zaatari, Ghazi, Alam, Samir, Skouri, Hadi N., Mahfouz, Rami A., Taher, Ali, and Zgheib, Nathalie K.

Subjects
ACADEMIC medical centers, ANALYSIS of variance, ANTICOAGULANTS, BIOTRANSFORMATION (Metabolism), BLOOD coagulation tests, FISHER exact test, GENES, GENETIC polymorphisms, HEME, HEMORRHAGE, HIGH performance liquid chromatography, HEALTH outcome assessment, PHARMACEUTICAL arithmetic, POLYMERASE chain reaction, REGRESSION analysis, RESEARCH funding, STATISTICS, SURVIVAL analysis (Biometry), T-test (Statistics), TIME, WARFARIN, DATA analysis, TREATMENT effectiveness, DATA analysis software
Abstract

The authors assessed the impact of CYP2C9*2, CYP2C9*3, and/or VKORC1-1639G>A/1173C>T single-nucleotide polymorphisms on oral anticoagulants in a Lebanese population. This study recruited 231 Lebanese participants on long-term warfarin or acenocoumarol maintenance therapy with an international normalized ratio (INR) monitored at the American University of Beirut Medical Center. CYP2C9 and VKORC1 variant alleles were screened by real-time PCR. Plasma R- and S-warfarin and R- and S-acenocoumarol levels were assayed using high-performance liquid chromatography. The variant allele frequencies of CYP2C9*2, CYP2C9*3, and VKORC1 -1639G>A/1173C>T were 15.4%, 7.8%, and 52.4%, respectively. Fifty-five participants were excluded from analysis because of nontherapeutic INR values at recruitment, leaving 43 participants taking warfarin and 133 taking acenocoumarol. There was a significant decrease in the weekly maintenance dose of both drugs with CYP2C9 and VKORC1 variants when compared with wild-type patients. CYP2C9*2 had the least impact on the response to both drugs. The concentrations of R- and S-warfarin in plasma were significantly correlated with CYP2C9 genotypes. For acenocoumarol, time to reach target INR was more prolonged in patients carrying any CYP2C9 variant allele but failed to reach statistical significance because of low numbers of patients. There was no association between allelic variants and bleeding events. This is the first pharmacogenetic study of oral anticoagulants in Arabs. The authors showed that both CYP2C9 and VKORC1 polymorphisms are common in Lebanon and influence warfarin and acenocoumarol dose requirements, with the CYP2C9*2 polymorphism having less effect on acenocoumarol, the most commonly used oral anticoagulant in Lebanon. [ABSTRACT FROM PUBLISHER]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results